New platform lets plan sponsors test obesity drug coverage without rebate complexity
Eli Lilly is testing whether a flat US$449 price for its obesity drug Zepbound can finally make GLP‑1 coverage workable for more employer plans.
According to Reuters, Lilly has launched the “Lilly Employer Connect” platform to help employers link with organizations that offer low‑cost benefits and comprehensive obesity‑care programs, with the aim of widening access to Zepbound while keeping plan costs more predictable.
Through the platform, the multi‑dose Zepbound KwikPen will be available to network pharmacies at a discounted net price of US$449 per month for all doses, with lower out‑of‑pocket costs for employees and greater cost transparency for employers.
As per CNBC, list prices for Zepbound and Lilly’s diabetes treatment Mounjaro are both above US$1,000 a month, and uneven employer coverage has left roughly half of people with commercial insurance unable to start or stay on obesity treatment.
CNBC cited a Peterson‑KFF Health System Tracker survey showing that nearly one‑fifth of firms with more than 200 workers, and 43 percent of those with 5,000 or more workers, cover GLP‑1 drugs for weight loss.
Lilly is pitching Employer Connect as a way to work around traditional benefit designs.
Reuters reported that the program provides employees access to weight‑loss medicines at lower out‑of‑pocket costs and gives employers greater cost predictability and transparency.
Kevin Hern, senior vice‑president of Lilly Employer, said that by enabling coverage outside traditional benefit designs, Lilly lowers barriers to treatment and gives employers greater control over how they support employee access to obesity care.
As per CNBC, Hern added that the US$449 net price does not involve rebates, which he said gives employers clearer visibility to decide whether they can offer the drug.
Design flexibility is a core feature.
Employers can use the platform to choose from more than a dozen independent program administrators to structure obesity benefits around their budget and workforce needs.
According to CNBC, some administrators focus on administering the obesity benefits – including enrolment, eligibility and claims – while others specialise in comprehensive obesity management with telehealth, nutrition and lifestyle support.
Reuters said the platform lets employers pair access to Zepbound KwikPen with in‑person or virtual clinical care and behaviour‑change support.
Lilly already works with more than 15 independent program administrators.
Reuters named GoodRx, Teladoc Health and Mark Cuban Cost Plus Drug Company, along with pharmacies such as HealthDyne and CenterWell.
CNBC reported that other administrators on the platform include Sesame, 9amHealth, Calibrate Health and several digital health and primary‑care providers, and that Lilly’s goal is to create a platform where these firms compete on the value of their services rather than on drug price.
Risk management around compounded versions of GLP‑1 drugs also features in the positioning.
Reuters reported that Teladoc Health executive Kelly Bliss said the program allows employers to adjust benefits to their workforce and guides employees to FDA‑approved treatments instead of compounded medications.
Lilly and its Danish rival Novo Nordisk have been trying to expand access to their weight‑loss treatments and eliminate unapproved compounded versions made by combining, mixing or altering drug ingredients.
On the supply side, Lilly has turned to artificial intelligence to support sustained access.
Forbes reported that Diogo Rau, Lilly’s chief information and digital officer, said AI allowed the company to make more GLP‑1 product last year by using a digital twin of its manufacturing facilities to increase output and spot injector defects more accurately.
Zepbound and Mounjaro together accounted for more than half of Lilly’s US$65bn in revenue last year, with Mounjaro sales reaching US$23bn, up from US$11.5bn, and Zepbound revenue rising to US$13.5bn from US$4.9bn.
